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Clostridium difficile infection is the leading cause of healthcare associated 
diarrhoea in Europe and North America
1, 2
. During infection, C. difficile produces 
two key virulence determinants, toxin A and toxin B. Experiments with purified 
toxins have suggested that toxin A alone is able to evoke the symptoms of C. 
difficile infection, but toxin B is unable to do so unless it is mixed with toxin A, or 
there is prior damage to the gut mucosa
3
. However, a recent study suggested that 
toxin B is essential for C. difficile virulence and that a strain producing toxin A 
alone was avirulent
4
. This creates a paradox over the individual importance of 
toxin A and toxin B. Here we show that isogenic mutants of C. difficile producing 
either toxin A or toxin B alone can cause fulminant disease in the hamster model of 
infection. By using a gene knock-out system
5, 6
 to permanently inactivate the toxin 
genes, we found that C. difficile producing either one or both toxins displayed 
cytotoxic activity in vitro, which translated directly into virulence in vivo. 
Furthermore, by constructing the first ever double mutant strain of C. difficile, in 
which both toxin genes were inactivated, we were able to completely attenuate 
virulence. Our findings re-establish the importance of both toxin A and toxin B 
and highlight the need to continue considering both toxins in the development of 
diagnostic tests and effective counter-measures against C. difficile. 
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Toxin A and toxin B both catalyse the glucosylation, and hence inactivation, of 
Rho-GTPases; small regulatory proteins of the eukaryotic actin cell cytoskeleton. This 
leads to disorganisation of the cell cytoskeleton and cell death
7
. The toxin genes, tcdA 
and tcdB, are situated on the C. difficile chromosome in a 19.6 kilobase pathogenicity 
locus (PaLoc), along with the three accessory genes, tcdC, tcdR and tcdE (Fig. 1a). To 
address the individual importance of toxin A and toxin B, we used the ClosTron gene 
knock-out system
6
 to inactivate the toxin genes of C. difficile. This system inactivates 
genes by inserting an intron into the protein-encoding DNA sequence of a gene, thus 
resulting in a truncated and non-functional protein. The intron sequence itself 
encompasses an erythromycin resistance determinant which permits selective isolation 
of mutants. Furthermore, it has been shown experimentally that the insertions are 
completely stable, meaning that inactivation of a gene is permanent
5
. 
Using the ClosTron system, we targeted insertions to tcdA and tcdB at nucleotide 
positions 1584 and 1511, respectively (Fig. 1a). In both cases, this placed the intron 
within DNA sequence encoding the toxin catalytic domain. Three separate isogenic 
mutants of the toxin A-positive, toxin B-positive (A
+
B
+
) C. difficile strain 630Δerm8 
were constructed; two 'single-mutants', with toxin profiles A
-
B
+
 and A
+
B
-
, respectively, 
and a 'double-mutant' with toxin profile A
-
B
-
. The A
-
B
-
 double-mutant was made from 
the A
+
B
-
 single-mutant by targeting tcdA with a second intron which carried the 
chloramphenicol / thiamphenicol resistance gene catP instead of the usual erythromycin 
resistance determinant. 
The genotype of each toxin mutant was characterised by PCR and DNA sequence 
analysis to confirm the exact location of each intron insertion made (data not shown). 
Southern blot analysis of EcoRV-digested genomic DNA samples, using an intron-
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specific probe, confirmed that the A
-
B
+
 and A
+
B
-
 mutants each had a single insertion, 
while the A
-
B
-
 mutant had a double insertion (Fig. 1b). It is noteworthy that three bands 
were expected for the A
-
B
-
 double-mutant strain because the catP gene harbours an 
EcoRV site. The phenotype of each strain was confirmed by Western blot analysis. Use 
of a toxin A-specific antibody-probe confirmed that the A
-
B
+
 and A
-
B
-
 mutants no 
longer produced toxin A (Fig. 1c). Likewise, use of a toxin B-specific antibody-probe 
confirmed that the A
+
B
-
 and A
-
B
-
 mutants no longer produced toxin B (Fig. 1d).  
Subsequently, in vitro cell cytotoxicity assays were carried out using HT29 
(human colon carcinoma) cells and Vero (African green monkey kidney) cells. Each of 
these cell lines is susceptible to both toxin A and toxin B, although HT29 cells are more 
sensitive to toxin A and Vero cells are more sensitive to toxin B
9
. The action of toxin A 
and toxin B causes the cells to 'round' (that is, lose morphology) and die; a phenomenon 
which is clearly visible by light microscopy. We incubated cultured cells for 24 h with 
4-fold dilution series of C. difficile culture supernatants. To obtain the most objective 
data set possible, we determined the endpoint titre of each dilution series, rather than 
implementing a subjective cell scoring system. Endpoint titre was defined as the first 
dilution in a series for which HT29 or Vero cell morphology was indistinguishable from 
the negative controls (that is, cells which had been incubated with uninoculated C. 
difficile culture medium).  
As expected, the A
-
B
-
 double toxin mutant did not display any cytotoxic activity 
towards either HT29 or Vero cells (Fig. 2a,b). Compared to the A
+
B
+
 parental strain, the 
A
-
B
+
 mutant displayed reduced toxicity towards HT29 cells, although the difference 
was not statistically significant, and a similar degree of toxicity towards Vero cells (Fig 
2a,b). These findings were anticipated given the respective sensitivities of HT29 cells 
and Vero cells to toxin A and toxin B
9
. However, unexpectedly, when compared to the 
A
+
B
+
 parental strain, the A
+
B
-
 mutant displayed increased toxicity towards HT29 cells, 
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although the difference was not statistically significant, and a similar degree of toxicity 
towards Vero cells (Fig. 2a,b). We reasoned that this may occur due to increased 
expression of toxin A by the A
+
B
-
 mutant; a phenomenon which has been reported 
previously
4
. Indeed, qRT-PCR analysis confirmed that expression of toxin A was an 
average of 3.3-fold greater in the A
+
B
-
 mutant than the A
+
B
+
 parental strain (data not 
shown). We do not know the reason for this. However, considering the respective 
sensitivities of HT29 and Vero cells to toxin A
9
, this finding explains our unexpected 
cytotoxicity results, even accounting for the fact that the A
+
B
-
 mutant does not produce 
any toxin B. 
To confirm that the cytotoxic activity we had observed on HT29 cells and Vero 
cells were indeed attributable to the respective actions of toxin A and toxin B, we 
carried out toxin neutralisation assays. Culture supernatants of each C. difficile toxin 
mutant and the A
+
B
+
 parental strain were incubated with either toxin A-specific or toxin 
B-specific neutralising antibodies, prior to inoculation onto HT29 and Vero cell 
monolayers. Importantly, culture supernatants were diluted equivalently such that, for 
the A
+
B
+
 parental strain, only toxin A activity was detected on HT29 cells and only 
toxin B activity was detected on Vero cells (that is, toxin B activity towards HT29 cells 
was diluted-out completely and toxin A activity towards Vero cells was diluted-out 
completely) (Fig. 2c,d). As expected, the toxin A-specific antibody neutralised all toxic 
activity produced by the A
+
B
-
 mutant and the toxin B-specific antibody neutralized all 
toxic activity produced by the A
-
B
+
 mutant (Fig. 2c,d). Interestingly, the increased 
production of toxin A by the A
+
B
-
 mutant was clearly visible in this assay, as the 
cytotoxic activity of this strain towards Vero cells was not diluted-out completely as it 
was for the A
+
B
+
 parental strain (Fig. 2d).  
Having fully characterised our C. difficile toxin mutants in vitro, we tested the 
virulence of each in the hamster model of infection. Hamsters were each challenged 
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with 100 spores of a single C. difficile strain, 5 days after an oral dose of clindamycin 
(30 mg/kg). Each toxin mutant and the A
+
B
+
 parental strain were administered to eight 
hamsters in total. All hamsters became colonised by the C. difficile strain administered 
between 1 and 3 days post-challenge, with the exception of one which received the A
+
B
-
 
single toxin mutant (Fig. 3a). Following colonisation, hamsters which received the A
+
B
+
 
parental strain, the A
-
B
+
 mutant or the A
+
B
-
 mutant all developed symptoms of C. 
difficile infection, which resulted in a mean time to death of 1.0 day, 1.3 days and 4.0 
days, respectively (Fig. 3b). In contrast, none of the hamsters colonised by the toxin null 
A
-
B
-
 double mutant developed any symptoms of disease during the 14-day experimental 
period, indicating that this strain is completely attenuated for virulence. Bacteriological 
and PCR analysis of caecum samples taken from each hamster post mortem confirmed 
that the only infecting strain of C. difficile was, indeed, the strain administered in every 
case, thus ruling out any possibility of cross-contamination between cages or 
contamination from the environment (Supplementary Fig. 1).  
In conclusion, it is clear that both toxin A and toxin B play an important role in C. 
difficile infection as we have shown here that a strain which produces either toxin on its 
own or both together is virulent. It is pertinent to question why we found that an A
+
B
-
 
strain of C. difficile is virulent; a result which is in direct contrast with a similar study 
published recently
4
. This discrepancy may arise due to inherent differences between the 
hamsters used in each study. However, perhaps more likely is that there is one or more 
key differences between the strains of C. difficile studied. Although both strains are 
erythromycin-sensitive derivatives of strain 630
10, 11
, they were isolated independently 
through serial sub-culture
8, 12
. Therefore, either strain could have acquired one or more 
secondary mutations, which may affect the action of either one or both of the toxins. 
However, it is notable that our findings align with those of previous studies which have 
suggested a role for both toxin A and toxin B in C. difficile infection
3, 13-15
. Moreover, 
given that the human colon is the principle site of pathology in patients infected with C. 
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difficile, it stands to reason that an A
+
B
-
 strain of C. difficile is virulent in vivo, as it is 
toxin A which displays the greatest cytotoxicity towards laboratory cultured human 
colon cells (that is, HT29 cells). 
It is important to note that inherent variability exists between the toxins of some 
C. difficile strains; particularly in the case of toxin B
16-19
. In practical terms, this means 
that the toxins from different strains can vary in enzymatic activity (that is, different 
GTPase substrates may be glucosylated) and/or host-cell specificity. Consequently, it is 
not appropriate to over-interpret our findings and make general conclusions about the 
toxins produced by all toxigenic strains of C. difficile. Nonetheless, our results clearly 
demonstrate that a strain of C. difficile producing either toxin A or toxin B alone may be 
virulent and thus we have re-established the importance of both toxins in C. difficile 
infection.  
It is interesting to note that a number of clinical cases of C. difficile infection have 
been attributed to naturally occurring A
-
B
+
 strains
20, 21
, but there have been no reports of 
naturally occurring A
+
B
-
 isolates to date. This would suggest that A
+
B
-
 strains do not 
exist, but it may also be an artefact of routine diagnostic testing practices. Either way, 
our results show that A
+
B
-
 strains may be virulent and even if they do not exist in nature 
already, they may yet evolve. Consequently, it is imperative that both toxin A and toxin 
B continue to be considered in routine diagnostic settings and in the development of 
effective countermeasures against C. difficile.  
 
Methods Summary 
Mutants were constructed from the parental strain C.  difficile 630erm8 using the 
ClosTron system
5, 6
. The retargeted plasmids pMTL007C-E2::Cdi-tcdA-1584s, 
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pMTL007C-E2::Cdi-tcdB-1511a and for the double pMTL007S-C7::Cdi-tcdA-1584s 
were transferred into C. difficile via conjugation. The single ClosTron mutants were 
isolated on erythromycin plates. The double mutant was isolated on thiamphenicol 
plates. 
For cytotoxicity assays, the four strains were grown overnight in 5 ml TY under 
anaerobic conditions as previously described
22
. The cell densities were standardised 
before centrifugation and filtration. Supernatants were diluted in a 4-fold series and 
20μl of dilutions were added onto monolayers of Vero and HT29 cells preincubated in 
96 well plates for 48 h (at 37C, 5% CO2). Cytotoxicity was recorded after 24 h. 
Statistical analysis was performed using one way ANOVA tests. For the neutralization 
assay appropriate dilutions of supernatants were pre-incubated with a suitable 
concentration of anti-TcdA or anti-TcdB serum (polyclonal, tgcBIOMICS) for 1 h at 
37C and then added as previously described to Vero and HT29 cells and evaluated 
after 24 h. Golden Syrian hamsters were dosed with clindamycin (30 mg/kg) 5 days 
prior to being infected orally with 100 spores each. Hamsters were monitored for signs 
of infection (including weight-loss, behavioural changes and wet-tail) and sacrificed 
when the endpoint was met. Faecal pellets were collected daily and plated to confirm 
the presence or absence of C. difficile.  Caecum samples were homogenized, plated and 
C. difficile counts obtained. PCR was performed to determine the C. difficile genotype 
isolated from all samples. Supplementary Information, showing PCR results, is linked 
to the online version of the paper at www.nature.com/nature. 
Full Methods and any associated references are available in the online version of the paper at 
www.nature.com/nature. 
Received 27/04/2010. 
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Figure 1. Characterization of C. difficile toxin mutants. a, The pathogenicity 
locus PaLoc of C. difficile 630 showing the intron insertion sites for the toxin 
mutants. b, Southern blot using an intron specific probe. The control plasmid 
(pMTL007C-E2) and the genomic DNA of the four strains was digested with 
EcoRV, which resulted in a band of ca. 9 kb for the plasmid, 10 kb for the tcdB-
mutation (in A+B- and A-B-), just over 3 kb for the tcdA-single mutant (A-B+) and 
1.8 and 1.2 kb for the tcdA-mutation in the double mutant, due to an additional 
EcoRV site in the catP gene. c, Western blot probing culture supernatants with 
anti-TcdA-antibody (tgcBIOMICS). d, Western blot probing culture supernatants 
with anti-TcdB-antibody (tgcBIOMICS). 
 
Figure 2. In vitro cytotoxicity. a and b, Supernatants of the parental strain 
A+B+ and the three mutants A-B+, A+B- and A-B- were used in cell culture assays 
to measure cytotoxicity. HT29 cells (a) and Vero cells (b) were cultured to a flat 
monolayer before adding C. difficile supernatants in 4-fold dilutions series. After 
a 24 h incubation toxin endpoint titres were determined. Data represent the 
mean  s.d.; n = 3. c and d, Toxin neutralization assays. Appropriate dilutions of 
supernatants were pre-incubated with a suitable concentration of anti-TcdA or 
anti-TcdB serum for 1 h at 37C and then added to HT29 cells (c) and Vero 
cells (d) which were evaluated after 24 h. Scale bar represents 2 mm. 
 
Figure 3. Virulence of C. difficile strains in hamsters. Groups of 8 hamsters 
were challenged with C. difficile 630 Δerm (A+B+), or one of the toxin mutant 
strains, A+B-, A-B+ or A-B-. a, Colonisation of Golden Syrian hamsters by each 
11 
 
strain is presented as time from inoculation to colonisation in days. n = 8. b, 
Time from colonisation to death. The duration of the experiment was set at 14 
days. n = 8. 
 
 
Methods 
Strains and growth conditions. Strains used in this study were E. coli TOP10 
(Invitrogen) as a cloning host, E. coli CA434
23
 as a conjugal donor and C. difficile 
630erm8 and mutants. All strains were stored at -80C stocks upon arrival and 
maintained as frozen stocks ever since.  E. coli cultures were grown on Luria Bertani 
medium, aerobically, 37C and shaking if liquid unless stated otherwise. C. difficile 
cultures were grown in BHIS
24
 or TY
25
, anaerobically, 37C in an anaerobic 
workstation (Don Whitley, UK). Antibiotics were used at the following concentrations 
where appropriate: Chloramphenicol (25 g/ml or 12.5 g/ml), thiamphenicol (15 
g/ml), spectinomycin (250 g/ml or 750 g/ml), erythromycin (2.5 g/ml), D-
cycloserine (250 g/ml) and cefoxitin (8 g/ml).  
Molecular biology techniques. Qiagen mini prep kits were used to purify plasmids. 
Genomic DNA was obtained by phenol-chloroform extraction. Digests, PCRs and DNA 
purification were all done according to general protocols
26
. DNA sequencing was 
performed by Geneservice, UK. 
Construction and characterization of mutants. The C. difficile single mutant strains 
A
-
B
+
 and A
+
B
-
 were made using ClosTron technology as described previously
5, 6
. The 
A
-
B
-
 double mutant strain was made from the A
+
B
-
 mutant using a catP-based ClosTron 
using the 'pseudo-suicide' vector principle as described elsewhere
25
. The following 
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retargeted plasmids pMTL007C-E2::Cdi-tcdA-1584s, pMTL007C-E2::Cdi-tcdB-1511a 
and for the double pMTL007S-C7::Cdi-tcdA-1584s were used. To verify the correct 
insertions, primers used for tcdA were: Cdi-tcdA-F2 (5´-
TCAATTGACAGAACAAGAAATAAATAGTCTATGGAGC-3´) and EBS universal
5
, 
and  Cdi-tcdA-R2 (5´-TACCCCATTGTCTTCAGAAAGAGATCCACC-3´) and 
ErmRAM-R (5´-ACGCGTGCGACTCATAGAATTATTTCCTCCCG-3´); and for tcdB 
were: Cdi-tcdB-F1 (5´-TGATAGTATAATGGCTGAAGCTAATGCAGATAATGG-
3´) and ErmRAM-R, and Cdi-tcdB-R1 (5´-
CTTGCATCGTCAAATGACCATAAGCTAGCC-3´) and EBS universal. 
Southern blotting. Mutants were verified by Southern blot using an intron specific 
probe. 2 μg genomic DNA were digested with EcoRV (NEB) overnight. The blot was 
carried out using a DIG high prime labelling and detection kit (Roche) according to the 
manufacturer’s instructions.  
Western blotting. Supernatants from 96 h cultures, grown anaerobically in TY, were 
concentrated 8-fold by chloroform-methanol-precipitation. Proteins were standardized 
and run on Tricine gels 10-20% (Invitrogen) and transferred onto nitrocellulose 
membrane. The membranes were blocked with milk powder and then incubated with 
mouse monoclonal anti-TcdA antibody TTC8 and mouse monoclonal anti-TcdB 
antibody 2CV (tgcBIOMICS) respectively, followed by protein A-HRP (Sigma). The 
ECL Western blot detection kit from Amersham was used according to the 
manufacturer’s instructions. 
Cell toxicity assays. The four strains were grown overnight in 5 ml TY under anaerobic 
conditions as previously described
22
, then the cell density was standardised, the cells 
centrifuged and supernatants filtered. Supernatants were diluted in a 4-fold series and 20 
μl of dilutions were added onto monolayers of Vero and HT29 cells preincubated in 96 
well plates for 48 h (at 37C, 5% CO2). Cytotoxicity was recorded after 24 h. For the 
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neutralization assay appropriate dilutions of supernatants were pre-incubated with a 
suitable concentration of anti-TcdA or anti-TcdB serum (polyclonal, tgcBIOMICS) for 
1 h at 37C. These were then added to Vero and HT29 cells which were evaluated after 
24 h.  
Vero and HT29 cells were grown in DMEM or McCoy's 5A, respectively, with 10% v/v 
foetal calf serum and 1% v/v penicillin-streptomycin at 37C, 5% CO2 until confluent. 
Cells were detached using trypsin, and seeded into 96 well plates at a density of ca. 2 × 
10
5
 cells/ml. All assays were carried out in triplicate. GraphPad Prism was used for 
statistical analysis. Significant differences were assessed using one way ANOVA tests. 
qRT-PCR. The qRT-PCR was carried out as described elsewhere
4
.  
Hamster infection model. We used a block design with final group sizes of 8 animals. 
Female Golden Syrian hamsters (100 – 130 g) were housed singly in individually 
ventilated cages. Each hamster was dosed with clindamycin (30 mg/kg) 5 days prior to 
being infected orally with 100 spores each. Hamsters were monitored for signs of 
infection and sacrificed when the endpoint was met. The hamsters were handled 
individually in a microbiological safety cabinet. In line with UK Home Office 
requirements to reduce animal suffering, an alternative to death was used as the end 
point. Animals were monitored 3-4 times per day following infection and were assessed 
for several parameters including presence and severity of diarrhoea, weight-loss, level 
of activity, starey coat, sunken eyes, hunched posture and response to stimulus.  A 
scoring system based on severity of changes observed (ranging from 0-3 for each 
parameter) was used to quantify changes in the condition of the animals which were 
euthanised when a pre-determined cumulative value was reached.  
Faecal pellets were collected daily and plated to determine the presence of C. difficile. 
Caecum samples from each hamster were homogenized, plated and C. difficile counts 
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obtained. PCR was performed to determine the genotype of each strain recovered from 
hamsters. Faecal and caecum samples were plated on Fructose agar (Clostridium 
difficile agar base, Oxoid) with cycloserine cefoxitin, taurocholate, tetracycline and 
amphotericin to select for Clostridium difficile. The following primer sets were used to 
authenticate the various strain genotypes: oligonucleotides 3800 and 10050
8
 to confirm 
the cells were derived from C. difficile 630erm, oligonucleotide primers Cdi-tcdA-F2 
(5´-TCAATTGACAGAACAAGAAATAAATAGTCTATGGAGC-3´) and Cdi-tcdA-
R2 (5´-TACCCCATTGTCTTCAGAAAGAGATCCACC-3´) to distinguish between 
the toxin A insertional mutants and wildtype, and the primers Cdi-tcdB-F1 (5´-
TGATAGTATAATGGCTGAAGCTAATGCAGATAATGG-3´) and Cdi-tcdB-R1 (5´-
CTTGCATCGTCAAATGACCATAAGCTAGCC-3´) to distinguish between the toxin 
B insertional mutation and wildtype. A figure showing annealing of the primers and gel 
pictures can be found in supplementary information, which is linked to the online 
version of the paper at www.nature.com/nature. 
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